# US 9,517,238 B2 · Compositions and methods for treating allergic inflammation through inhibition of NTRK1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,517,238 B2
- Document ID: US9517238B2
- Status: Granted
- Kind: B2
- Application number: 14/934,589
- Filed: 2015-11-06
- Published: 2016-05-12
- Granted: 2016-12-13
- Earliest claimed: 2014-11-07
- Assignees: Children's Hospital Medical Center
- Applicants: Children's Hospital Medical Center
- Inventors: Mark Rochman; Marc E. Rothenberg
- Web page: https://patentgrep.com/patent/US9517238B2

## CPC

- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides methods of treating allergic inflammatory conditions using an anti-neurotrophin tyrosine kinase receptor 1 (NTRK1)-based therapeutic agent, and related compositions and methods.

## Claims

### Claim 1

A method of treating eosinophilic esophagitis (EoE) in a human subject in need thereof, comprising administering to the subject an amount of a tyrosine kinase inhibitor effective to suppress NTRK1 activity in target cells of the human subject, wherein the tyrosine kinase inhibitor is lestaurtinib (CEP-701) or crizotinib.

### Claim 2 (depends on 1)

The method of claim 1, wherein the target cells are epithelial cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the target cells are cells of a target tissue in the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the target tissue is tracheal, lung, or esophageal tissue.

### Claim 5 (depends on 1)

The method of claim 1, wherein the tyrosine kinase inhibitor is effective to suppress NTRK1 activity in the cells of the subject, relative to untreated cells.

### Claim 6 (depends on 5)

The method of claim 5, wherein the tyrosine kinase inhibitor is effective to suppress NTRK1 gene expression or protein expression, or both.

### Claim 7 (depends on 1)

The method of claim 1, wherein the amount of the tyrosine kinase inhibitor is effective to ameliorate one or more symptoms of the EoE.

### Claim 8 (depends on 1)

The method of claim 1, further comprising administering to the subject at least one additional active agent.

### Claim 9 (depends on 8)

The method of claim 8, wherein the at least one additional active agent is an anti-inflammatory agent.

### Claim 10 (depends on 8)

The method of claim 8, wherein the at least one additional active agent is an IL-13 inhibitor, a non-steroidal anti-inflammatory drug (NSAID), a cytokine inhibitor, or a steroid.